Stockhub

Toleranzia AB: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

16 August 2022

  • curprev 08:4208:42, 16 August 2022 >Paris 721 bytes +721 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. It also intends to develop TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease. In addition, the company develops tolerogens technology, a treatmen..."
Retrieved from "https://stockhub.co/research/Toleranzia_AB"